- favorable pharmacokinetic and safety data observed in first clinical
trial of novel Fleximer(TM) anticancer agent -
CAMBRIDGE, Mass., Oct. 24 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced interim results of a Phase I study of its lead product candidate, XMT-1001, in patients with advanced solid tumors. The data was presented by Edward A. Sausville, M.D., Ph.D, Professor of Medicine and Associate Director for Clinical Research, University of Maryland Greenebaum Cancer Center in a poster session on October 23 at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics taking place in San Francisco, CA. Full text of the abstract #A146 "A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients with Advanced Solid Tumors" can be viewed online at the AACR website at http://www.aacr.org. XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity.
Commenting on the data, Robert J. Fram, M.D. Chief Medical Officer at Mersana, stated: "The Phase I results show that, in humans, camptothecin, the active agent in XMT-1001, is released gradually from the Fleximer carrier as a pro-drug in a manner that will potentially avoid common safety problems associated with drugs in this class. To date, we've seen no evidence of drug-related serious adverse events and the study is ongoing."
Results were presented from 12 patients enrolled in an ongoing Phase I
open-label, dose-escalation trial designed to determine the safety,
tolerability and pharmacokinetic profile of XMT-1001. To date, XMT-1001 has
been well tolerated in patients and no serious drug related adverse events
have been reported. Preliminary results demonstrate a favorable
pharmacokinetic profile with low levels of CPT, both total and free,
recovered in urine. The ma
|SOURCE Mersana Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved